165 related articles for article (PubMed ID: 12893762)
1. High-dose therapy in multiple myeloma.
Bladé J; Vesole DH; Gertz Morie
Blood; 2003 Nov; 102(10):3469-70. PubMed ID: 12893762
[No Abstract] [Full Text] [Related]
2. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
Dodero A; Perfetti V; Ciceri F; Corradini P
Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
[No Abstract] [Full Text] [Related]
3. Stem cell transplantation in multiple myeloma.
Björkstrand B
Hematology; 2005; 10 Suppl 1():26-8. PubMed ID: 16188627
[No Abstract] [Full Text] [Related]
4. Stem cell transplantation for multiple myeloma: current status and future directions.
Caldera H; Giralt S
Curr Hematol Rep; 2004 Jul; 3(4):249-56. PubMed ID: 15217554
[TBL] [Abstract][Full Text] [Related]
5. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
Vesole DH; Simic A; Lazarus HM
Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
[TBL] [Abstract][Full Text] [Related]
6. Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation.
Mai EK; Schmitt T; Radujkovic A; König L; Goldschmidt H; Ho AD; Luft T; Müller-Tidow C; Dreger P; Hegenbart U; Schönland SO
Br J Haematol; 2022 Jan; 196(1):244-248. PubMed ID: 34431093
[No Abstract] [Full Text] [Related]
7. Con: allogeneic transplantation in multiple myeloma.
van Rhee F
Clin Adv Hematol Oncol; 2006 May; 4(5):391-4. PubMed ID: 16728948
[No Abstract] [Full Text] [Related]
8. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
[No Abstract] [Full Text] [Related]
9. Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.
Rosko A; Hofmeister C; Benson D; Efebera Y; Huang Y; Gillahan J; Byrd JC; Burd CE
Bone Marrow Transplant; 2015 Oct; 50(10):1379-81. PubMed ID: 26121107
[No Abstract] [Full Text] [Related]
10. Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Respond to author.
Zhang K; Gao C; Tang Q
Support Care Cancer; 2019 Sep; 27(9):3171-3172. PubMed ID: 30868268
[No Abstract] [Full Text] [Related]
11. Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.
Cook G
Bone Marrow Transplant; 2015 Oct; 50(10):1269-70. PubMed ID: 26237169
[No Abstract] [Full Text] [Related]
12. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e59-63. PubMed ID: 24378319
[No Abstract] [Full Text] [Related]
13. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
[TBL] [Abstract][Full Text] [Related]
14. [Treatment outcome of hematopoietic stem cell transplantation for multiple myeloma].
Shimazaki C
Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1331-6. PubMed ID: 16097588
[No Abstract] [Full Text] [Related]
15. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation in multiple myeloma.
Pant S; Copelan EA
Biol Blood Marrow Transplant; 2007 Aug; 13(8):877-85. PubMed ID: 17640590
[TBL] [Abstract][Full Text] [Related]
17. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.
Moor I; Bacher VU; Jeker B; Taleghani BM; Mueller BU; Keller P; Betticher D; Egger T; Novak U; Pabst T
Bone Marrow Transplant; 2018 Dec; 53(12):1599-1602. PubMed ID: 29884856
[No Abstract] [Full Text] [Related]
18. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
19. Tandem bone marrow transplantation in multiple myeloma.
Chng WJ
N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
[No Abstract] [Full Text] [Related]
20. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
[No Abstract] [Full Text] [Related]
[Next] [New Search]
